Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations Actively Enrolling Patients Across Multiple Sites in Clinical Study to Investigate...
-
CRANBURY, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and...
-
Broad Label for All Fabry Patients with an Amenable Genetic Mutation Conference Call Today at 12:30 pm ET CRANBURY, N.J., April 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a...
-
CRANBURY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has initiated a reimbursed...
-
CRANBURY, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that...
-
New Phase 3 Data for Migalastat for Fabry Disease Demonstrate Persistence of Positive Renal and Cardiac Effects and Substrate Reduction in Important Kidney Cell Type (Podocytes) Preclinical...
-
Committee for Medicinal Products for Human Use (CHMP) Opinion on Migalastat for Fabry Disease Likely in March Clinical Study Underway to Investigate Novel Enzyme Replacement Therapy for...
-
CRANBURY, N.J., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, will host a conference call...
-
CRANBURY, N.J., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that 3...
-
CRANBURY, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has strengthened its...